Cite

HARVARD Citation

    Taylor, M. et al. (2015). Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online]. 
  
Back to record